
Prevest Denpro (PREVEST) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
184.5M
Gross Profit
160.0M
86.70%
Operating Income
60.8M
32.92%
Net Income
51.4M
27.86%
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
69.6M
Shareholders Equity
1.1B
Debt to Equity
0.07
Cash Flow Metrics
Revenue & Profitability Trend
Prevest Denpro Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 630.3M | 559.1M | 498.5M | 381.1M | 274.4M |
Cost of Goods Sold | 122.5M | 135.6M | 126.1M | 97.8M | 78.9M |
Gross Profit | 507.8M | 423.5M | 372.5M | 283.3M | 195.5M |
Gross Margin % | 80.6% | 75.8% | 74.7% | 74.3% | 71.2% |
Operating Expenses | |||||
Research & Development | - | - | - | - | 1.6M |
Selling, General & Administrative | - | 72.0M | 52.1M | 34.8M | 39.8M |
Other Operating Expenses | 173.4M | 56.7M | 39.8M | 30.6M | 27.5M |
Total Operating Expenses | 173.4M | 128.8M | 91.9M | 65.4M | 68.8M |
Operating Income | 201.8M | 187.8M | 191.3M | 147.0M | 85.7M |
Operating Margin % | 32.0% | 33.6% | 38.4% | 38.6% | 31.2% |
Non-Operating Items | |||||
Interest Income | - | 25.4M | 16.2M | 13.2M | 5.1M |
Interest Expense | 0 | 0 | 0 | 1.0M | 1.9M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 242.5M | 214.3M | 209.6M | 160.5M | 93.4M |
Income Tax | 60.9M | 53.0M | 52.5M | 44.8M | 21.3M |
Effective Tax Rate % | 25.1% | 24.7% | 25.0% | 27.9% | 22.8% |
Net Income | 181.6M | 161.4M | 157.1M | 115.7M | 72.1M |
Net Margin % | 28.8% | 28.9% | 31.5% | 30.4% | 26.3% |
Key Metrics | |||||
EBITDA | 261.5M | 227.1M | 216.3M | 166.7M | 99.8M |
EPS (Basic) | - | ₹13.45 | ₹13.09 | ₹9.64 | ₹8.16 |
EPS (Diluted) | - | ₹13.45 | ₹13.09 | ₹9.64 | ₹8.16 |
Basic Shares Outstanding | - | 12003000 | 12000000 | 12000000 | 8835000 |
Diluted Shares Outstanding | - | 12003000 | 12000000 | 12000000 | 8835000 |
Income Statement Trend
Prevest Denpro Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 609.0M | 486.1M | 390.0M | 423.2M | 164.2M |
Short-term Investments | 47.0M | 16.6M | 11.9M | 7.3M | 4.4M |
Accounts Receivable | 76.7M | 81.3M | 43.0M | 23.2M | 37.5M |
Inventory | 80.4M | 62.4M | 47.9M | 32.6M | 12.7M |
Other Current Assets | 23.1M | 1.9M | 744.0K | 593.0K | 593.0K |
Total Current Assets | 857.2M | 680.7M | 543.2M | 527.0M | 236.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 268.1M | 13.6M | 3.2M | 4.8M | 4.1M |
Goodwill | - | 0 | 0 | 0 | 0 |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | - | - | - |
Total Non-Current Assets | 268.1M | 267.5M | 74.1M | 114.4M | 70.7M |
Total Assets | 1.1B | 948.2M | 617.2M | 641.4M | 306.8M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 16.2M | 11.9M | 14.0M | 16.4M | 39.1M |
Short-term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 42.5M | 11.9M | 2.4M | 4.1M | 3.7M |
Total Current Liabilities | 59.6M | 55.1M | 54.4M | 54.0M | 65.5M |
Non-Current Liabilities | |||||
Long-term Debt | 0 | 0 | 0 | 13.7M | 13.9M |
Deferred Tax Liabilities | 10.0M | 6.9M | 3.7M | 2.9M | 2.4M |
Other Non-Current Liabilities | - | 1.0K | - | -25.0M | 1.0K |
Total Non-Current Liabilities | 10.0M | 6.9M | 3.7M | 16.6M | 16.3M |
Total Liabilities | 69.6M | 62.0M | 58.1M | 70.5M | 81.8M |
Equity | |||||
Common Stock | 120.0M | 120.0M | 120.0M | 120.0M | 2.8M |
Retained Earnings | - | 564.1M | 405.9M | 248.8M | 217.8M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.1B | 886.2M | 728.0M | 570.9M | 225.0M |
Key Metrics | |||||
Total Debt | 0 | 0 | 0 | 13.7M | 13.9M |
Working Capital | 797.5M | 625.6M | 488.8M | 473.0M | 170.6M |
Balance Sheet Composition
Prevest Denpro Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 242.5M | 214.3M | 209.6M | 160.5M | 93.4M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -20.3M | -37.6M | -40.9M | -11.8M | -16.8M |
Operating Cash Flow | 185.4M | 151.8M | 152.6M | 135.7M | 73.3M |
Investing Activities | |||||
Capital Expenditures | -19.7M | -37.3M | -135.3M | -48.9M | -22.3M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -19.7M | -37.3M | -135.3M | -48.9M | -22.3M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -12.0M | -3.2M | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | - |
Financing Cash Flow | -12.0M | -3.2M | 0 | 266.1M | -1.3M |
Free Cash Flow | 128.5M | 78.9M | -28.6M | 20.7M | 65.2M |
Net Change in Cash | 153.7M | 111.3M | 17.3M | 352.9M | 49.6M |
Cash Flow Trend
Prevest Denpro Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
36.86
Price to Book
6.35
Price to Sales
10.63
Profitability Ratios
Profit Margin
28.81%
Operating Margin
32.92%
Return on Equity
18.70%
Return on Assets
12.17%
Financial Health
Current Ratio
14.38
Debt to Equity
0.00
Beta
0.50
Per Share Data
EPS (TTM)
₹15.14
Book Value per Share
₹87.89
Revenue per Share
₹52.53
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
prevest | 6.7B | 36.86 | 6.35 | 18.70% | 28.81% | 0.00 |
Poly Medicure | 195.3B | 56.51 | 7.17 | 15.99% | 20.28% | 6.52 |
Dr Agarwal's Health | 140.4B | 625.56 | 7.45 | 6.61% | 4.88% | 49.87 |
Laxmi Dental | 21.8B | 64.42 | 10.33 | 25.70% | 13.29% | 9.35 |
Tarsons Products | 19.9B | 66.74 | 3.15 | 4.79% | 7.59% | 53.82 |
Centennial Surgical | 558.2M | 2,482.50 | 1.82 | -4.65% | -2.74% | 108.97 |
Financial data is updated regularly. All figures are in the company's reporting currency.